Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab vs ustekinumab vs placebo in moderately to severely active Crohn's disease (GALAXI 1/2/3, Japan subset)
jRCT2080223893Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (9 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Efficacy of guselkumab in moderately to severely active Crohn's disease and Safety and tolerability of guselkumab. Started May 2018; status: completed.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080223893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223893.